Commentary|Videos|November 19, 2026

Dr Janjigian on Biomarkers to Guide First-Line Treatment in HER2+ Gastroesophageal Cancer

Yelena Y. Janjigian, MD, discusses how HER2 expression and PD-L1 status inform first-line treatment selection in gastroesophageal cancer.

“You need to pay attention both to PD-L1 and HER2 expression [during first-line decision-making].”

Yelena Y. Janjigian, MD, chief of the Gastrointestinal Oncology Service and the Carroll and Milton Petrie Chair at Memorial Sloan Kettering Cancer Center, discussed how HER2 expression, and PD-L1 status help inform first-line treatment selection for patients with HER2-positive gastroesophageal adenocarcinoma.

Janjigian described an evolving landscape following the August 2026 FDA approval of zanidatamab-hrii (Ziihera)–based combinations. The approval included:

zanidatamab in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr (Tevimbra) as first-line treatment for adult patients with HER2-positive (immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH] positive), unresectable locally advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma, as detected by an FDA-approved test

zanidatamab in combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for adult patients with HER2-positive (IHC 3+) unresectable locally advanced or metastatic gastric, GEJ, or esophageal adenocarcinoma, as detected by an FDA-approved test

She highlighted data from the phase 3 HERIZON-GEA-01 (NCT05152147), which showed that zanidatamab plus chemotherapy, with or without tislelizumab, improved progression-free survival (PFS) and overall survival (OS) vs trastuzumab (Herceptin) plus chemotherapy. When approaching a treatment decision in the frontline setting, she emphasized that the appropriate regimen depended on the tumor’s biomarker profile, as indicated by the FDA, noting the PD-L1 expression also plays a role beyond HER2 expression.

Importantly, Janjigian explained that the comparator arm of HERIZON-GEA-01 did not include pembrolizumab (Keytruda) plus trastuzumab and chemotherapy; this regimen received traditional approval from the FDA in August 2025 for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) of at least 1, based on data from the phase 3 KEYNOTE-811 (NCT03615326). She described the KEYNOTE-811 regimen as a United States standard.

For real-world treatment selection, Janjigian emphasized examining the degree of HER2 expression rather than treating HER2 positivity as a single category, noting the importance of distinguishing between different levels of IHC expression.

Janjigian explained the FDA indications are crucial for guiding treatment with the zanidatamab-based combinations, cautioning against the use of zanidatamab plus chemotherapy without immunotherapy for patients with HER2 IHC 2+/ISH+ tumors, highlighting less favorable outcomes in that subgroup in the absence of immunotherapy.

PD-L1 status provide another distinction between the HERIZON-GEA-01 and KEYNOTE-811 approaches. For patients with PD-L1-positive disease, she noted that pembrolizumab plus trastuzumab remains a treatment option and noted that a minimum CPS is not required with the zanidatamab-based combinations. Accordingly, Janjigian highlighted the latter combination as an option even for patients with CPS 0 tumors, but she noted that a CPS score of 0 is rare for patients with HER2-positive tumors.


Related to this article